Table 2.
Demographic, clinical, and imaging data for all participants in this study
| HC (n = 90) | MCI (n = 139) | AD (n = 66) | |
|---|---|---|---|
| Age, Mean (SE) |
76.0 (0.6) |
75.1 (0.7) |
75.4 (0.9) |
| Female, % |
51 |
33 |
41 |
| Education Years, Mean (SE) |
15.6 (0.3) |
16.1 (0.2) |
15.1 (0.4) |
| MMSE, Mean (SE) |
29.1 (0.1) |
26.7 (0.1) |
23.4 (0.2) |
| CDR-SB, Mean (SE) |
0.03 (0.01) |
1.5 (0.07) |
4.2 (0.2) |
| APOE ϵ4 carriers (%) |
24 |
54 |
71 |
| CSF H-FABP level (ng/ml), Mean (SE) |
0.38 (0.03) |
0.54 (0.02) |
0.58 (0.03) |
| CSF Aβ1–42 level (pg/ml), Mean (SE) |
207.8 (5.6) |
157.5 (4.1) |
141.5 (2.6) |
| CSF p-tau181p level (pg/ml), Mean (SE) |
24.7 (1.4) |
36.8 (1.3) |
41.7 (2.6) |
| Entorhinal Cortex APC, Mean (SE) |
-0.8 (0.1) |
-2.4 (0.1) |
-2.9 (0.2) |
| AD-vulnerable ROI APC, Mean (SE) | -1.1 (0.1) | -3.2 (0.2) | -3.9 (0.3) |
MCI; mild cognitive impairment, HC; cognitively normal older adults, AD; Alzheimer’s disease, MMSE; Mini-mental status exam, CDR-SB; Clinical dementia rating-sum of boxes score, APC; Annualized percent change, SE; Standard error of the mean.